Combination therapy of an inhibitor of group VIA phospholipase A 2 with paclitaxel is highly effective in blocking ovarian cancer development

American Journal of Pathology

Volumn 179, Issue 1, 2011, Pages 452-461

  Li, Hui ^a   Zhao, Zhenwen ^a   Antalis, Caryl ^a   Zhao, Zhanzhong ^a   Emerson, Robert ^a   Wei, Gang ^a   Zhang, Sheng ^a   Zhang, Zhong Yin ^a   Xu, Yan ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOENOL LACTONE; CISPLATIN; FKGK 11; PACLITAXEL; PHOSPHOLIPASE A2 INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GROUP IV PHOSPHOLIPASES A2; HUMANS; IMMUNOENZYME TECHNIQUES; KETONES; MICE; MICE, INBRED NOD; MICE, SCID; NAPHTHALENES; OVARIAN NEOPLASMS; PACLITAXEL; PHOSPHODIESTERASE INHIBITORS; PYRONES;

EID: 80052464802     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2011.03.027     Document Type: Article

References (41)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer Statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. S. Sengupta, Z. Wang, R. Tipps, and Y. Xu Biology of LPA in health and disease Semin Cell Dev Biol 15 2004 503 512
3. Y. Xu, D. Wang, and Z. Wang Lipid generation and signaling in ovarian cancer Cancer Treat Res 149 2009 241 267
4. Y. Xu, S. Sengupta, S. Singh, and R. Steinmetz Novel lipid signaling pathways in ovarian cancer cells Cell Sci Rev 3 2006 168 197
5. G.B. Mills, and W.H. Moolenaar The emerging role of lysophosphatidic acid in cancer Nat Rev Cancer 3 2003 582 591
6. T.V. Do, J.C. Symowicz, D.M. Berman, L.A. Liotta, E.F. Petricoin III, M.S. Stack, and D.A. Fishman Lysophosphatidic acid down-regulates stress fibers and up-regulates pro-matrix metalloproteinase-2 activation in ovarian cancer cells Mol Cancer Res 5 2007 121 131
7. D.A. Fishman, Y. Liu, S.M. Ellerbroek, and M.S. Stack Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells Cancer Res 61 2001 3194 3199
8. G.B. Mills, A. Eder, X. Fang, Y. Hasegawa, M. Mao, Y. Lu, J. Tanyi, F.H. Tabassam, J. Wiener, R. Lapushin, S. Yu, J.A. Parrott, T. Compton, W. Tribley, D. Fishman, M.S. Stack, D. Gaudette, R. Jaffe, T. Furui, J. Aoki, and J.R. Erickson Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer Cancer Treat Res 107 2002 259 283
9. J. Symowicz, B.P. Adley, M.M. Woo, N. Auersperg, L.G. Hudson, and M.S. Stack Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells Cancer Res 65 2005 2234 2242
10. K.S. Kim, S. Sengupta, M. Berk, Y.G. Kwak, P.F. Escobar, J. Belinson, S.C. Mok, and Y. Xu Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo Cancer Res 66 2006 7983 7990
11. S. Sengupta, K.S. Kim, M.P. Berk, R. Oates, P. Escobar, J. Belinson, W. Li, D.J. Lindner, B. Williams, and Y. Xu Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion Oncogene 26 2007 2894 2901
12. H. Li, D. Wang, H. Zhang, K. Kirmani, Z. Zhao, R. Steinmetz, and Y. Xu Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent mice Mol Cancer Ther 8 2009 1692 1701
13. J. Aoki, A. Inoue, and S. Okudaira Two pathways for lysophosphatidic acid production Biochim Biophys Acta 1781 2008 513 518
14. S. Okudaira, H. Yukiura, and J. Aoki Biological roles of lysophosphatidic acid signaling through its production by autotaxin Biochimie 92 2010 698 706
15. X. Zhao, D. Wang, Z. Zhao, Y. Xiao, S. Sengupta, Y. Xiao, R. Zhang, K. Lauber, S. Wesselborg, L. Feng, T.M. Rose, Y. Shen, J. Zhang, G. Prestwich, and Y. Xu Caspase-3-dependent activation of calcium-independent phospholipase A2 enhances cell migration in non-apoptotic ovarian cancer cells J Biol Chem 281 2006 29357 29368
16. J. Ren, Y.J. Xiao, L.S. Singh, X. Zhao, Z. Zhao, L. Feng, T.M. Rose, G.D. Prestwich, and Y. Xu Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells Cancer Res 66 2006 3006 3014
17. S. Sengupta, Y.J. Xiao, and Y. Xu A novel laminin-induced LPA autocrine loop in the migration of ovarian cancer cells FASEB J 17 2003 1570 1572
18. H. Li, Z. Zhao, G. Wei, L. Yan, D. Wang, H. Zhang, G.E. Sandusky, J. Turk, and Y. Xu Group VIA phospholipase A2 in both host and tumor cells is involved in ovarian cancer development FASEB J 24 2010 4103 4116
19. Y. Song, P. Wilkins, W. Hu, K.S. Murthy, J. Chen, Z. Lee, R. Oyesanya, J. Wu, S.E. Barbour, and X. Fang Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells Biochem J 406 2007 427 436
20. P.S. Steeg, and D. Theodorescu Metastasis: a therapeutic target for cancer Nat Clin Pract Oncol 5 2008 206 219
21. H.A. Kenny, T. Krausz, S.D. Yamada, and E. Lengyel Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum Int J Cancer 121 2007 1463 1472
22. A. Jatoi, K.C. Podratz, P. Gill, and L.C. Hartmann Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer J Support Oncol 2 2004 323 327
23. S. Bao, D.J. Miller, Z. Ma, M. Wohltmann, G. Eng, S. Ramanadham, K. Moley, and J. Turk Male mice that do not express group VIA phospholipase A2 produce spermatozoa with impaired motility and have greatly reduced fertility J Biol Chem 279 2004 38194 38200
24. L.A. van Meeteren, P. Ruurs, C. Stortelers, P. Bouwman, M.A. van Rooijen, J.P. Pradere, T.R. Pettit, M.J. Wakelam, J.S. Saulnier-Blache, C.L. Mummery, W.H. Moolenaar, and J. Jonkers Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development Mol Cell Biol 26 2006 5015 5022
25. Y. Xu, X.J. Fang, G. Casey, and G.B. Mills Lysophospholipids activate ovarian and breast cancer cells Biochem J 309 pt 3 1995 933 940
26. Y. Xu, D.C. Gaudette, J.D. Boynton, A. Frankel, X.J. Fang, A. Sharma, J. Hurteau, G. Casey, A. Goodbody, and A. Mellors Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients Clin Cancer Res 1 1995 1223 1232
27. S.L. Hazen, L.A. Zupan, R.H. Weiss, D.P. Getman, and R.W. Gross Suicide inhibition of canine myocardial cytosolic calcium-independent phospholipase A2: mechanism-based discrimination between calcium-dependent and -independent phospholipases A2 J Biol Chem 266 1991 7227 7232
28. J.F. Yeo, W.Y. Ong, S.F. Ling, and A.A. Farooqui Intracerebroventricular injection of phospholipases A2 inhibitors modulates allodynia after facial carrageenan injection in mice Pain 112 2004 148 155
29. J.E. Burke, and E.A. Dennis Phospholipase A2 structure/function, mechanism, and signaling J Lipid Res 50 Suppl 2009 S237 S242
30. R. Lopez-Vales, X. Navarro, T. Shimizu, C. Baskakis, G. Kokotos, V. Constantinou-Kokotou, D. Stephens, E.A. Dennis, and S. David Intracellular phospholipase A(2) group IVA and group VIA play important roles in Wallerian degeneration and axon regeneration after peripheral nerve injury Brain 131 2008 2620 2631
31. C. Baskakis, V. Magrioti, N. Cotton, D. Stephens, V. Constantinou- Kokotou, E.A. Dennis, and G. Kokotos Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes J Med Chem 51 2008 8027 8037
32. A. Kalyvas, C. Baskakis, V. Magrioti, V. Constantinou-Kokotou, D. Stephens, R. Lopez-Vales, J.Q. Lu, V.W. Yong, E.A. Dennis, G. Kokotos, and S. David Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis Brain 132 2009 1221 1235
33. K.L. Sodek, T.J. Brown, and M.J. Ringuette Collagen I but not Matrigel matrices provide an MMP-dependent barrier to ovarian cancer cell penetration BMC Cancer 8 2008 223
34. D.A. Fishman, A. Kearns, K. Chilukuri, L.M. Bafetti, E.A. O'Toole, J. Georgacopoulos, M.J. Ravosa, and M.S. Stack Metastatic dissemination of human ovarian epithelial carcinoma is promoted by α2β1-integrin-mediated interaction with type I collagen Invasion Metastasis 18 1998 15 26
35. A. Tokumura, E. Majima, Y. Kariya, K. Tominaga, K. Kogure, K. Yasuda, and K. Fukuzawa Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase J Biol Chem 277 2002 39436 39442
36. M. Umezu-Goto, Y. Kishi, A. Taira, K. Hama, N. Dohmae, K. Takio, T. Yamori, G.B. Mills, K. Inoue, J. Aoki, and H. Arai Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production J Cell Biol 158 2002 227 233
37. S.B. Daniels, E. Cooney, M.J. Sofia, P.K. Chakravarty, and J.A. Katzenellenbogen Haloenol lactones: potent enzyme-activated irreversible inhibitors for α-chymotrypsin J Biol Chem 258 1983 15046 15053
38. S.B. Daniels, and J.A. Katzenellenbogen Halo enol lactones: studies on the mechanism of inactivation of α-chymotrypsin Biochemistry 25 1986 1436 1444
39. J. Balsinde, and E.A. Dennis Bromoenol lactone inhibits magnesium-dependent phosphatidate phosphohydrolase and blocks triacylglycerol biosynthesis in mouse P388D1 macrophages J Biol Chem 271 1996 31937 31941
40. H. Song, S. Ramanadham, S. Bao, F.F. Hsu, and J. Turk A bromoenol lactone suicide substrate inactivates group VIA phospholipase A2 by generating a diffusible bromomethyl keto acid that alkylates cysteine thiols Biochemistry 45 2006 1061 1073
41. S.R. McWhinney, R.M. Goldberg, and H.L. McLeod Platinum neurotoxicity pharmacogenetics Mol Cancer Ther 8 2009 10 16